GlassScriptPhysician profile
Richard D Murray
NPI 1265499891
$2,573.75
in general payments reported to CMS, 2019-2025
30 companies · $675 in 2025
The $675 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.11 · 2020: $87.95 · 2021: $458 · 2022: $386 · 2023: $436 · 2024: $444 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $344.89 | 2021-2025 | |
| Abbvie INC. | $275.45 | 2019-2025 | |
| Exeltis, USA INC. | $208.60 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $197.03 | 2021-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $185.35 | 2019-2025 | Aptima |
| Sumitomo Pharma America, INC. | $174.93 | 2023-2025 | Myfembree |
| Organon LLC | $159.57 | 2021-2025 | Nexplanon |
| Pfizer INC. | $133.60 | 2019-2025 | |
| Myovant Sciences INC. | $107.17 | 2021-2022 | |
| Heron Therapeutics, INC. | $104.33 | 2024 | Aponvie |
| Bayer Healthcare Pharmaceuticals INC. | $103.07 | 2021-2025 | |
| Exact Sciences Corporation | $96.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Coopersurgical, INC. | $69.67 | 2020-2024 | Paragard T 380a, Sos |
| Baxter Healthcare | $65.89 | 2021-2025 | Perclot |
| Merck Sharp & Dohme LLC | $55.59 | 2022-2023 | Gardasil 9 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Channel Medsystems, INC. | $35.21 | 2023-2025 | |
| Allergan, INC. | $31.69 | 2019 | |
| Amgen INC. | $30.31 | 2020-2025 | Evenity |
| Evofem Biosciences, INC. | $28.51 | 2021-2022 | |
| Avion Pharmaceuticals | $28.14 | 2021-2022 | |
| Axonics, INC. | $18.37 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.80 | 2021 | |
| Daiichi Sankyo INC. | $17.43 | 2021 | |
| Biogen, INC. | $15.95 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $15.26 | 2019 | |
| Ascend Therapeutics US, LLC | $15.00 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.84 | 2021 | |
| Urovant Sciences INC | $13.14 | 2022 | |
| Medicem INC. | $11.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.